Company Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 18/07/2025 BST			5-day change	1st Jan Change
16.76 ^USD	-11.09%		-8.47%	-10.85%

07-08	Arrowhead Pharmaceuticals, Inc., Q2 2025 Earnings Call, May 12, 2025
07-08	Arrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia	CI

Business description: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

Number of employees: 609

Sales by Activity: Arrowhead Pharmaceuticals, Inc.

Fiscal Period: September	2020	2021	2022	2023	2024
Nanotechnology	87.99M	138M	243M	241M	-

See all business segments

Geographical breakdown of sales: Arrowhead Pharmaceuticals, Inc.

Fiscal Period: September	2020	2021	2022	2023	2024
United States	87.99M	138M	243M	241M	-

See all geographic segments

Executive Committee: Arrowhead Pharmaceuticals, Inc.

Manager	Title	Age	Since
Christopher Anzalone CEO	Chief Executive Officer	55	30/11/2007
Daniel J. Apel DFI	Director of Finance/CFO	-	12/05/2025
Bruce Given COO	Chief Operating Officer	70	25/10/2011
Peter Carignan CTO	Chief Tech/Sci/R&D Officer	-	31/07/2022
Patrick O'brien CMP	Compliance Officer	61	30/11/2014

See ARROWHEAD PHARMACEUTICALS, INC. governance

Composition of the Board of Directors: Arrowhead Pharmaceuticals, Inc.

Director	Title	Age	Since
Christopher Anzalone BRD	Director/Board Member	55	30/11/2007
Mauro Ferrari BRD	Director/Board Member	65	18/08/2010
Michael Perry BRD	Director/Board Member	65	18/12/2011
William Waddill BRD	Director/Board Member	68	31/12/2017
Adeoye Olukotun BRD	Director/Board Member	80	31/08/2020
Victoria Vakiener BRD	Director/Board Member	61	01/05/2022
Hong Bo Lu BRD	Director/Board Member	54	31/03/2024
Douglas Ingram BRD	Director/Board Member	62	05/02/2025

Composition of the Board of Directors

Shareholders: Arrowhead Pharmaceuticals, Inc.

Name	Equities	%	Valuation
BlackRock Advisors LLC 15.11 %	19,054,486	15.11 %	301 M $
Vanguard Fiduciary Trust Co. 10.47 %	13,202,562	10.47 %	209 M $
SAREPTA THERAPEUTICS, INC. 9.458 %	11,926,301	9.458 %	188 M $
Avoro Capital Advisor LLC 8.811 %	11,111,111	8.811 %	176 M $
STATE STREET CORPORATION 5.551 %	6,999,249	5.551 %	111 M $

List of ARROWHEAD PHARMACEUTICALS, INC. shareholders

Company details: Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals, Inc.

177 East Colorado Boulevard Suite 700

91105, Pasadena

+626 304 3400

http://www.arrowheadpharma.com

address Arrowhead Pharmaceuticals, Inc.(ARWR)

Bio Therapeutic Drugs

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
ARROWHEAD PHARMACEUTICALS, INC.	-11.09%	-8.47%	-40.78%	-60.72%	2.31B
ARGENX SE	+0.24%	+2.39%	+15.57%	+35.09%	35.09B
WUXI APPTEC CO., LTD.	+1.95%	+7.06%	+108.59%	-18.67%	32.89B
BIONTECH SE	-0.92%	-2.54%	+28.74%	-33.21%	27.09B
INSMED INCORPORATED	-1.55%	+4.46%	+34.99%	+333.64%	19.48B
SUMMIT THERAPEUTICS INC.	-5.18%	+4.80%	+198.24%	+2,239.29%	19.46B
AKESO, INC.	+0.86%	+24.29%	+249.57%	+515.75%	16.09B
WUXI BIOLOGICS (CAYMAN) INC.	+0.88%	+7.13%	+154.00%	-62.61%	14.8B
GENMAB A/S	-0.07%	+3.01%	-23.33%	-44.07%	13.63B
EXELIXIS, INC.	-0.89%	-0.87%	+96.77%	+103.62%	12.13B
Average	-1.58%	+4.01%	+82.24%	+300.81%	19.3B
Weighted average by Cap.	-0.49%	+4.62%	+85.46%	+298.87%